Concepts (88)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fusion Proteins, bcr-abl | 2 | 2016 | 32 | 0.490 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2011 | 6 | 0.370 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2011 | 118 | 0.350 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 170 | 0.330 |
Why?
|
| Arthroplasty, Replacement, Shoulder | 2 | 2019 | 6 | 0.320 |
Why?
|
| Androgen-Binding Protein | 2 | 2002 | 3 | 0.250 |
Why?
|
| Mutation | 3 | 2016 | 2456 | 0.230 |
Why?
|
| Carrier Proteins | 2 | 2002 | 697 | 0.180 |
Why?
|
| Bone Transplantation | 1 | 2019 | 24 | 0.160 |
Why?
|
| Shoulder Joint | 1 | 2019 | 24 | 0.160 |
Why?
|
| Prosthesis Failure | 1 | 2019 | 71 | 0.160 |
Why?
|
| Hospitals, Special | 1 | 2018 | 9 | 0.150 |
Why?
|
| Orthopedics | 1 | 2018 | 27 | 0.150 |
Why?
|
| Collateral Ligaments | 1 | 2018 | 2 | 0.150 |
Why?
|
| Operating Rooms | 1 | 2018 | 55 | 0.150 |
Why?
|
| Tibial Fractures | 1 | 2018 | 13 | 0.150 |
Why?
|
| Multiple Trauma | 1 | 2018 | 27 | 0.150 |
Why?
|
| Knee Injuries | 1 | 2018 | 47 | 0.140 |
Why?
|
| Racquet Sports | 1 | 2016 | 4 | 0.130 |
Why?
|
| Shoulder Injuries | 1 | 2016 | 10 | 0.130 |
Why?
|
| Leukemia, Myeloid | 1 | 2016 | 32 | 0.130 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 46 | 0.130 |
Why?
|
| Inpatients | 1 | 2018 | 291 | 0.120 |
Why?
|
| Athletic Injuries | 1 | 2016 | 71 | 0.120 |
Why?
|
| Knee Joint | 1 | 2018 | 285 | 0.120 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 193 | 0.120 |
Why?
|
| Phosphoproteins | 1 | 2016 | 211 | 0.120 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2011 | 68 | 0.090 |
Why?
|
| Drug Design | 1 | 2011 | 136 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 1 | 2011 | 868 | 0.080 |
Why?
|
| Cell Survival | 1 | 2011 | 559 | 0.080 |
Why?
|
| Protein Conformation | 1 | 2011 | 763 | 0.070 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 1368 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2011 | 941 | 0.070 |
Why?
|
| Signal Transduction | 1 | 2016 | 2903 | 0.060 |
Why?
|
| Phosphatidylethanolamine Binding Protein | 2 | 2002 | 2 | 0.060 |
Why?
|
| Phospholipid Transfer Proteins | 2 | 2002 | 4 | 0.060 |
Why?
|
| Male | 5 | 2019 | 27743 | 0.060 |
Why?
|
| Incidence | 2 | 2018 | 1238 | 0.050 |
Why?
|
| Phosphatidylcholines | 1 | 2002 | 34 | 0.050 |
Why?
|
| X-Ray Diffraction | 1 | 2002 | 58 | 0.050 |
Why?
|
| Crystallization | 1 | 2002 | 97 | 0.050 |
Why?
|
| Mice | 2 | 2016 | 10294 | 0.050 |
Why?
|
| Humans | 7 | 2019 | 59374 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 381 | 0.050 |
Why?
|
| Glenoid Cavity | 1 | 2019 | 1 | 0.040 |
Why?
|
| Bone Resorption | 1 | 2019 | 41 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2019 | 127 | 0.040 |
Why?
|
| Range of Motion, Articular | 1 | 2019 | 85 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 5119 | 0.040 |
Why?
|
| Aged | 3 | 2019 | 13406 | 0.040 |
Why?
|
| Operative Time | 1 | 2018 | 76 | 0.040 |
Why?
|
| Joint Instability | 1 | 2018 | 39 | 0.040 |
Why?
|
| Radiography | 1 | 2019 | 516 | 0.040 |
Why?
|
| Middle Aged | 3 | 2019 | 16312 | 0.040 |
Why?
|
| Injury Severity Score | 1 | 2018 | 101 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2018 | 244 | 0.040 |
Why?
|
| Age Distribution | 1 | 2018 | 249 | 0.040 |
Why?
|
| Animals | 2 | 2016 | 19650 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2002 | 695 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2019 | 6070 | 0.030 |
Why?
|
| Acromioclavicular Joint | 1 | 2016 | 1 | 0.030 |
Why?
|
| Shoulder Dislocation | 1 | 2016 | 9 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 414 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2016 | 17 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 169 | 0.030 |
Why?
|
| Universities | 1 | 2016 | 144 | 0.030 |
Why?
|
| Athletes | 1 | 2016 | 97 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 1078 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2016 | 228 | 0.030 |
Why?
|
| Students | 1 | 2016 | 202 | 0.030 |
Why?
|
| United States | 2 | 2018 | 7425 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 2338 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 1597 | 0.030 |
Why?
|
| Female | 3 | 2019 | 30720 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 411 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2016 | 1997 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 4986 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 4272 | 0.020 |
Why?
|
| Adolescent | 1 | 2018 | 5835 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2002 | 253 | 0.010 |
Why?
|
| Adult | 1 | 2018 | 15679 | 0.010 |
Why?
|
| Crystallography, X-Ray | 1 | 2002 | 424 | 0.010 |
Why?
|
| Ligands | 1 | 2002 | 411 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2002 | 656 | 0.010 |
Why?
|
| Binding Sites | 1 | 2002 | 881 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2002 | 1128 | 0.010 |
Why?
|
| Protein Binding | 1 | 2002 | 1555 | 0.010 |
Why?
|